Synthes announces first quarter 2005 sales results
Solothurn/Switzerland, April 20, 2005Synthes sales grew by 19.6% for the first quarter 2005 versus prior year results. Pro forma for the acquisition of Mathys’ Osteosynthesis business as though the acquisition had occurred on January 1, 2004, sales for the first quarter grew by 13.7%.
Synthes consolidated sales were US$ 502.9 million for the first quarter of 2005. Foreign exchange positively impacted sales growth by 2.2% (2.1% for pro forma sales).
Key figures (unaudited)
|
 |
1) Includes Mathys sales from date of acquisition in February 2004 to December 2004 only.
2) Pro forma consolidated sales include the sales of the Mathys companies for all of 2004.
Continued growth in all segments driven by expanded sales force and increased training activities
The Trauma and CMF division growth in Q1 2005 continued to out-pace the market. The spine division grew at a slower pace than historical growth rates due to the timing of new product introductions. New product introductions are anticipated to drive an acceleration of spine sales growth in the second half of 2005.
Synthes: A leading medical device company
Synthes is a leading global medical device company. We develop, produce and market instruments, implants and biomaterials for the surgical fixation, correction and regeneration of the human skeleton and its soft tissues.
For further information please contact
Peter Fehlmann, Investor Relations, Synthes, Inc.
Phone: +41 32 720 48 10 , Fax: +41 32 720 48 11
e-mail: ir.info@synthes.com